This rare disease-focused stock pipeline is underrated, says insurance-starting analyst

  • Cantor Fitzgerald coverage has begun on KemPharm Inc (NASDAQ: KMPH) with Overweight rating and rating $20 price target.

  • According to the analyst, KMPH’s products, processes and execution capabilities are undervalued. As a result, increased earnings estimate revisions and advances in the pipeline should drive the stock higher.

  • KMPH focuses on rare central nervous system and related disorders. KMPH’s AZSTARYS is the first and only approved methylphenidate-based drug containing serdexmethylphenidate (SDX) indicated for attention deficit hyperactivity disorder (ADHD).

  • The FDA approved the drug in March 2021.

  • The company has shifted focus to rare diseases with arimoclomol for NPC (Niemann-Pick disease) and KP1077 for a rare sleep disorder.

  • Cantor also believes that KP1077 can capture a large share of the idiopathic insomnia market based on its clinical distinction and combined use.

  • Total cash of $107.4 million is expected runway in 2026.

  • Price action: KMPH stock is trading up 2.85% at $4.52 on Thursday’s final check.

Latest ratings for KMPH




Are from


January 2022

HC Wainwright & Co.




April 2021

HC Wainwright & Co.



March 2021

HC Wainwright & Co.

low class



See more analyst ratings for KMPH

See the latest analyst ratings

See more from Benzinga

Don’t miss real-time alerts on your stocks – join Benzinga Pro free! Try the tool that helps you invest smarter, faster and more efficiently.

© 2022 Benzinga does not provide investment advice. Copyright Registered.


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button